Related Experiment Video
Updated: Mar 4, 2026
10:30
Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
Published on: January 25, 2017
9.3K
Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations
Sarah Rotondo-Trivette1, William Jennings2, David Fudman3
1Division of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, TX, USA.
Current Gastroenterology Reports
|June 4, 2025
Summary
Interleukin-23 (IL-23) inhibitors are safe and effective for moderate-to-severe inflammatory bowel disease, showing success even after other biologic treatments failed. These treatments appear more effective than ustekinumab for Crohn's disease.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Inflammatory bowel disease (IBD) encompasses Crohn's disease and ulcerative colitis.
- Biologic therapies have revolutionized IBD management.
- Interleukin-23 (IL-23) is a key cytokine in IBD pathogenesis.
Purpose of the Study:
- To review the literature on IL-23 inhibitors for IBD.
- To discuss the role of IL-23 inhibitors in current clinical practice.
Main Methods:
- Literature review of pivotal trials and clinical studies.
- Analysis of efficacy, safety, and comparative data.
Main Results:
- IL-23 inhibitors are effective in inducing and maintaining remission in moderate-to-severe IBD.
- These agents demonstrate safety with low adverse events.
- IL-23 inhibitors show potential superiority over ustekinumab in Crohn's disease, particularly in patients with prior biologic failure.
Conclusions:
- IL-23 inhibitors represent a significant advancement in IBD treatment.
- They offer a safe and effective therapeutic option for moderate-to-severe IBD.
- Clinical choice among IL-23 inhibitors may depend on practical factors, despite similar efficacy.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
664
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
664
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
614
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
614
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
579
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
579
01:29Inflammatory Bowel Disease IV: Pharmacological Management
868
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
868
01:29Drugs for Treatment of Ulcerative Colitis in IBD
577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
980
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
980